← Leaderboards
Gary G. Altman
Cambium Oncology Llc
$902,914
Attributed
$1,805,827
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2024–25$2M$1.5M$1M$500K$0
'24
'25
Funding mix
By agency
NIH$1,805,827 · 2
By mechanism
R44$1,805,827 · 2
Top collaborators
- Edmund K. Waller2 shared
- Sarwish Rafiq1 shared
Others in their field
Other Rising Stars on “Novel Therapeutics”
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Angee Greer · Ppd Development Lp$82,531,927
- Suma Babu · Massachusetts General Hospital$26,348,733
- Sabrina Paganoni · Massachusetts General Hospital$26,348,733
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Cynthia M Visness · Rho Federal Systems Division, Inc.$13,531,908
Research focus
Novel TherapeuticsT-LymphocyteIn VivoMouse ModelPharmacodynamicsSurvival RateHalf-LifeInnovationMalignant NeoplasmsMortalityOncologyPharmaceutical PreparationsSignal TransductionSmall Business Innovation Research GrantDrug CandidateExhibitsHematologic NeoplasmsImmunotherapeutic AgentLeadMalignant Neoplasm Of PancreasAntagonistCancer CellBiological MarkersToxic Effect
Grant awards (3)
Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia$999,997
R44 · FY2025 · CA · contact PI
Development of a Novel Armored CAR-T Immunotherapeutic for Pancreatic Cancer$400,835
R44 · FY2025 · CA · contact PI
Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia$404,995
R44 · FY2024 · CA · contact PI